The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus

被引:0
作者
Che, Pulin [1 ,2 ]
Wang, Lihua [2 ]
Li, Qianjun [1 ,2 ]
机构
[1] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2009年 / 2卷 / 04期
关键词
Dengue virus; high throughput screening; HTS; cytopathic effect; CPE; assay development; assay optimization; assay validation; antiviral;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Dengue virus (DENV) is listed as one of the NIAID Category A priority pathogens. Dengue disease is endemic in most tropical countries, with an estimated 2.5 billion people living in areas at risk of DENV infection. Due to the lack of vaccines and antiviral drugs, it is now a huge public health burden around the world. In order to screen large compound libraries for the identification of novel antivirals targeting DENV, it is essential to develop a high throughput screening (HTS) amenable assay. Here, we present the development, optimization and validation of a cytopathic effect-based assay against Dengue virus serotype-2 (DENV-2). The assay conditions, including cell culturing conditions, DMSO tolerance and the multiplicity of infection, were optimized in both 96- and 384-well plates. Assay robustness and reproducibility were determined under the optimized conditions in 96-well plate, including Z'-value of 0.71, signal-to-background ratio of 6.88, coefficient of variation of 6.3% in mock-infected cells and 12.3% in DENV-2 infected cells. This assay was further miniaturized into a 384-well plate format with similar assay robustness and reproducibility comparing with these in the 96-well plate format. This assay was then validated using the LOPAC(1280) compound library, demonstrating its repeatability with comparable assay robustness and reproducibility. This fully developed and validated HTS amenable assay could be used in future studies to screen large compound libraries for the identification of novel antivirals against dengue disease.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 31 条
[1]  
Ahmed J, 2009, EURO SURVEILL, V14
[2]  
[Anonymous], 2002, Dengue and Dengue Hemorrhagic Fever Fact Sheet
[3]   Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses [J].
Bolken, TC ;
Laquerre, S ;
Zhang, YM ;
Bailey, TR ;
Pevear, DC ;
Kickner, SS ;
Sperzel, LE ;
Jones, KF ;
Warren, TK ;
Lund, SA ;
Kirkwood-Watts, DL ;
King, DS ;
Shurtleff, AC ;
Guttieri, MC ;
Deng, YJ ;
Bleam, M ;
Hruby, DE .
ANTIVIRAL RESEARCH, 2006, 69 (02) :86-97
[5]   α-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum [J].
Courageot, MP ;
Frenkiel, MP ;
Santos, CDD ;
Deubel, V ;
Desprès, P .
JOURNAL OF VIROLOGY, 2000, 74 (01) :564-572
[6]   Inhibition of flavivirus infections by antisense oligorners specifically suppressing viral translation and RNA replication [J].
Deas, TS ;
Binduga-Gajewska, I ;
Tilgner, M ;
Ren, P ;
Stein, DA ;
Moulton, HM ;
Iversen, PL ;
Kauffman, EB ;
Kramer, LD ;
Shi, PY .
JOURNAL OF VIROLOGY, 2005, 79 (08) :4599-4609
[7]  
Despres P, 1998, J VIROL, V72, P823
[8]   Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA [J].
Diamond, MS ;
Zachariah, M ;
Harris, E .
VIROLOGY, 2002, 304 (02) :211-221
[9]   Quantitative cell-based high-content screening for vasopressin receptor agonists using Transfluoro® technology [J].
Ghosh, RN ;
DeBiasio, R ;
Hudson, CC ;
Ramer, ER ;
Cowan, CL ;
Oakley, RH .
JOURNAL OF BIOMOLECULAR SCREENING, 2005, 10 (05) :476-484
[10]   Impact of climate change and other factors on emerging arbovirus diseases [J].
Gould, E. A. ;
Higgs, S. .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2009, 103 (02) :109-121